Cost of introducing and delivering malaria vaccine (RTS,S/AS01<sub>E</sub>) in areas of seasonal malaria transmission, Mali and Burkina Faso
Halimatou Diawara(Unknown), Ranju Baral(Program for Appropriate Technology in Health), Alassane Dicko(Ministère de la Santé et de l'Hygiène Publique), Cynthia Lee(Program for Appropriate Technology in Health), Seydou Yabré(Université Ouaga II), Rosemonde Guissou(Institut de Recherche en Sciences de la Santé), Fatoumata Koita(Université des Sciences, des Techniques et des Technologies de Bamako), Seydou Traoré, Ann Levin(Morgan, Lewis & Bockius (United States)), Winthrop Morgan(Morgan, Lewis & Bockius (United States)), Fadima Yaya Bocoum(Institut de Recherche en Sciences de la Santé), Clint Pecenka(Program for Appropriate Technology in Health), Jean‐Bosco Ouédraogo(Institut de Recherche en Sciences de la Santé)
Cited by 12
Related Papers
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345
Predicting the likelihood and intensity of mosquito infection from sex specific Plasmodium falciparum gametocyte density
|eLife|2018|143